JPH11180895A - 血管新生阻害剤 - Google Patents

血管新生阻害剤

Info

Publication number
JPH11180895A
JPH11180895A JP10267388A JP26738898A JPH11180895A JP H11180895 A JPH11180895 A JP H11180895A JP 10267388 A JP10267388 A JP 10267388A JP 26738898 A JP26738898 A JP 26738898A JP H11180895 A JPH11180895 A JP H11180895A
Authority
JP
Japan
Prior art keywords
human
antibody
ctgf
vascular endothelial
endothelial cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP10267388A
Other languages
English (en)
Japanese (ja)
Inventor
Masaharu Takigawa
正春 滝川
Toru Nakanishi
徹 中西
Takeshi Shimo
剛 志茂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Tobacco Inc
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Priority to JP10267388A priority Critical patent/JPH11180895A/ja
Priority to PCT/JP1998/004124 priority patent/WO1999013910A1/fr
Publication of JPH11180895A publication Critical patent/JPH11180895A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP10267388A 1997-09-12 1998-09-04 血管新生阻害剤 Pending JPH11180895A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP10267388A JPH11180895A (ja) 1997-09-12 1998-09-04 血管新生阻害剤
PCT/JP1998/004124 WO1999013910A1 (fr) 1997-09-12 1998-09-11 Inhibiteurs de neovascularisation

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP9-267943 1997-09-12
JP26794397 1997-09-12
JP10267388A JPH11180895A (ja) 1997-09-12 1998-09-04 血管新生阻害剤

Publications (1)

Publication Number Publication Date
JPH11180895A true JPH11180895A (ja) 1999-07-06

Family

ID=26547849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10267388A Pending JPH11180895A (ja) 1997-09-12 1998-09-04 血管新生阻害剤

Country Status (2)

Country Link
JP (1) JPH11180895A (fr)
WO (1) WO1999013910A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523928A (ja) * 2002-04-30 2005-08-11 アルコン，インコーポレイテッド 眼内圧の低下および緑内障性網膜症／眼神経障害の処置の両方のための独特の手段としての、結合組織増殖因子（ｃｔｇｆ）の活性および／または発現を調節するか、阻害するか、または調整する薬剤
JP2007525194A (ja) * 2003-06-04 2007-09-06 ファイブロジェン，インコーポレイテッド 結合組織成長因子抗体

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1463531B1 (fr) * 2001-12-11 2011-09-28 Fibrogen, Inc. Procede pour inhiber des processus oculaires
EP1925306A3 (fr) * 2002-04-30 2008-09-17 Alcon, Inc. Agents regulant, inhibant ou modulant l'activite et/ou l'expression du facteur de croissance du tissu conjonctif (ctgf) pour reduire la pression intraoculaire
US20050271670A1 (en) 2004-04-28 2005-12-08 Spong Suzanne M Treatments for cancer
AU2006244148A1 (en) 2005-05-05 2006-11-16 Fibrogen, Inc. Cardiovascular disease therapies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5408040A (en) * 1991-08-30 1995-04-18 University Of South Florida Connective tissue growth factor(CTGF)
JPH08225462A (ja) * 1994-12-01 1996-09-03 Toagosei Co Ltd ワクチン
WO1996039486A1 (fr) * 1995-06-05 1996-12-12 Human Genome Sciences, Inc. Facteur de croissance humain du type ccn

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005523928A (ja) * 2002-04-30 2005-08-11 アルコン，インコーポレイテッド 眼内圧の低下および緑内障性網膜症／眼神経障害の処置の両方のための独特の手段としての、結合組織増殖因子（ｃｔｇｆ）の活性および／または発現を調節するか、阻害するか、または調整する薬剤
JP2006131643A (ja) * 2002-04-30 2006-05-25 Alcon Inc 眼内圧の低下および緑内障性網膜症／眼神経障害の処置の両方のための独特の手段としての、結合組織増殖因子（ｃｔｇｆ）の活性および／または発現を調節するか、阻害するか、または調整する薬剤
JP2007525194A (ja) * 2003-06-04 2007-09-06 ファイブロジェン，インコーポレイテッド 結合組織成長因子抗体
JP2012143239A (ja) * 2003-06-04 2012-08-02 Fibrogen Inc 結合組織成長因子抗体

Also Published As

Publication number Publication date
WO1999013910A1 (fr) 1999-03-25

Similar Documents

Publication Publication Date Title
WO2020019135A1 (fr) Anticorps anti-cd47 et son utilisation
JP4212278B2 (ja) 移植片拒絶反応抑制剤
JP5166398B2 (ja) ヒトタンパク質チロシンホスファターゼβ（ＨＰＴＰβ）に結合する抗体及びその使用
US7541438B2 (en) Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
JP6955721B2 (ja) ＲＧＭａ結合タンパク質及びその使用
JP2000095800A (ja) エリトロポエチン受容体を活性化する抗体
AU2007231687A1 (en) Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
JP2001206899A (ja) ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
KR101560843B1 (ko) 페리오스틴의 Ｅｘｏｎ-17 부위에 의해 코드되는 펩티드에 대한 항체를 함유하는 암 치료제
EP3235507B1 (fr) Application d'une molécule de liaison comme protéine précurseur du facteur neurotrophique dérivé du cerveau à liaison spécifique
WO1999059636A1 (fr) Inhibiteurs de l'activite du facteur de croissance endothelial vasculaire (vegf)
JP2002530066A (ja) Ｒｈａｍｍアンタゴニスト抗体
JP2000080100A (ja) 副甲状腺ホルモン関連タンパクに対するヒトモノクローナル抗体
JP2024026683A (ja) 末梢神経障害又は末梢神経障害若しくはアストロサイト障害が認められる疾患に伴う疼痛の予防又は治療方法
CN114364694B (zh) 靶向usag-1分子的用于牙齿再生治疗的中和抗体
JPH11180895A (ja) 血管新生阻害剤
JP4537507B2 (ja) 結合組織増殖因子に対するモノクローナル抗体及びその医薬用途
JP2003529370A (ja) 血管浸透性に対する有害な作用を有さないｖｅ−カドヘリンに対する拮抗薬抗体
US20060233790A1 (en) Immunoglobulin/hydrophilic peptide complexes
JP7572668B2 (ja) 歯の再生治療のためのｕｓａｇ－１を標的分子とした中和抗体
JP2004121001A (ja) ＴＧＦ−βＩＩ型受容体に対する高親和性モノクローナル抗体
WO2021145435A1 (fr) Agent prophylactique ou thérapeutique contre la démence
WO2024207616A1 (fr) Anticorps ciblant de manière spécifique b7-h4, son procédé de préparation et son utilisation
CN118742563A (zh) 靶向usag-1分子的用于牙齿再生治疗的中和抗体
JPH1087509A (ja) 腫瘍転移抑制剤

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050815

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20060425

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080826

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090310